InflaRx N.V.

IFRX

NL0012661870

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:59:47 04/06/2024 BST			5-day change	1st Jan Change
1.59 ^USD	+0.63%		+8.90%	-2.45%

05-08	InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-21	Transcript : InflaRx N.V. - Special Call

InflaRx N.V. Promotes Korinna Pilz as Chief Clinical Development Officer

August 05, 2021 at 12:30 pm

InflaRx N.V. announced that Dr. Korinna Pilz has been promoted effective August 1, 2021, to the newly created role of Chief Clinical Development Officer.

Latest news about InflaRx N.V.

InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Transcript : InflaRx N.V. - Special Call	03-21
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
InflaRx N.V. Appoints Jan Medina as Head of Investor Relations	02-22	CI
HC Wainwright Adjusts Price Target on InflaRx to $8 From $9, Keeps Buy Rating	01-25	MT
Transcript : InflaRx N.V. - Special Call	01-04
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose Phase I Study with C5aR Inhibitor INF904	01-04	CI
InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum	11-06	CI
Top Premarket Gainers	11-03	MT
InflaRx N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01	CI
Top Premarket Gainers	21/09/23	MT
Transcript : InflaRx N.V. - Special Call	11/09/23
InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose Phase I Study with C5aR Inhibitor INF904	11/09/23	CI
InflaRx Says Regulatory Review in Europe of Marketing Application for COVID-19 Drug Candidate Underway	30/08/23	MT
Inflarx N.V.'S Marketing Authorization Application for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency	30/08/23	CI
InflaRx N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Top Premarket Gainers	08/08/23	MT
Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023	28/06/23	CI
InflaRX Commercially Launches Gohibic to Treat Seriously Ill COVID-19 Patients in US	21/06/23	MT
InflaRx N.V. Announces Commercial Launch of Gohibic (Vilobelimab) in the U.S. for the Treatment of Critically Ill Covid-19 Patients	21/06/23	CI
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 11-JUN-2023.	10/06/23	CI
WuXi Biologics to Partner with Germany's InflaRx for Manufacture of COVID-19 Treatment	18/05/23	MT
Hong Kong Stocks Slump; Wuxi Bio Drops 4%	17/05/23	MT
InflaRx, WuXi Biologics Sign Manufacturing Deal for COVID-19 Drug	16/05/23	MT
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 Patients	16/05/23	CI

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Sector

Biotechnology & Medical Research

Calendar

05:00pm - R&D Day

More about the company

Income Statement Evolution

More financial data

Ratings for InflaRx N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.452 EUR

Average target price

8.375 EUR

Spread / Average Target

+476.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INFLARX N.V.	-2.45%	93.04M
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	123B
REGENERON PHARMACEUTICALS, INC.	+13.04%	107B
BIONTECH SE	-5.80%	24.01B
ARGENX SE	+2.21%	22.59B
GENMAB A/S	-10.09%	18.16B
WUXI APPTEC CO., LTD.	-40.52%	16.84B
BEIGENE, LTD.	-14.00%	16.23B
NEUROCRINE BIOSCIENCES, INC.	+1.18%	13.43B
SAREPTA THERAPEUTICS, INC.	+24.18%	11.32B

Bio Therapeutic Drugs

InflaRx N.V.

Equities

IFRX

NL0012661870

Biotechnology & Medical Research

InflaRx N.V. Promotes Korinna Pilz as Chief Clinical Development Officer

Latest news about InflaRx N.V.

Chart InflaRx N.V.

Company Profile

Income Statement Evolution

Ratings for InflaRx N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs